Shares of Helix BioPharma Corp. (OTCMKTS:HBPCF – Get Free Report) traded up 1.1% during trading on Wednesday . The stock traded as high as $0.45 and last traded at $0.45. 400 shares changed hands during trading, an increase of 7,307% from the average session volume of 5 shares. The stock had previously closed at $0.45.
Helix BioPharma Stock Performance
The stock has a market capitalization of $22.30 million, a price-to-earnings ratio of -4.55 and a beta of 0.06. The firm’s fifty day simple moving average is $0.45 and its 200 day simple moving average is $0.60.
Helix BioPharma (OTCMKTS:HBPCF – Get Free Report) last posted its quarterly earnings data on Monday, December 16th. The company reported ($0.02) EPS for the quarter.
About Helix BioPharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.
Featured Stories
- Five stocks we like better than Helix BioPharma
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- P/E Ratio Calculation: How to Assess Stocks
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
